Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OCEA: And it moves AGAIN!!
OCEA...............................................https://stockcharts.com/h-sc/ui?s=OCEA&p=W&b=5&g=0&id=p86431144783
#OCEA 🔥 crazy 300% today! More next week? $OCEA
all you have to do is look on yahoo finance bud.
Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics
Virion Therapeutics, Ocean Biomedical begin patient dosing in phase 1b trial of VRON-0200 immunotherapy for chronic HBV infection
Philadelphia
Friday, October 27, 2023
Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean Biomedical, Inc., announced that the first patients have been dosed in the phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus (HBV) infection.
VRON-0200, a first-in-class treatment, using one of Virion's proprietary checkpoint modifiers, was specifically designed to enhance and broaden a patient's own immune response. This novel mechanism of action may help overcome one of the key problems faced in treating chronic HBV - immune exhaustion. The international, first-in-human VRON-0200 phase 1b study is currently enrolling patients in Hong Kong and New Zealand, with additional sites planned in the United States. Initial clinical data from this study are expected in early 2024.
"The initiation and dosing of patients in this VRON-0200 study is a critical first step in evaluating its impact on chronically HBV-infected patient's immune responses to the virus, with the ultimate goal of finding a cure for this insidious disease. The mechanism by which VRON-0200 works is a totally new approach to anything previously investigated or currently in development by others – we are looking forward to evaluating the first clinical data from this program, early next year," said Dr. Sue Currie, COO of Virion.
Despite a preventative vaccine, cases of chronic hepatitis B (HBV) continue to rise, with an estimated 296 million persons infected worldwide and 820,000 deaths per year from HBV-related liver complications. This includes almost 100 million persons in China who are affected by this disease. Chronic HBV remains a global health issue with a high unmet medical need as there is no cure available. The current standard of care requires lifelong antiviral therapy to keep the virus in check.
Grace Wong, MD, Professor of Medicine at the Chinese University at Hong Kong (CUHK), and a principal investigator in the VRON-0200 study, commented, "Novel treatments that can control or potentially cure chronic HBV infection, that are easy to administer, and are well tolerated, alone, or in combination with other treatments, are in high need." Wong added, "VRON-0200, with its potential to expand a patient's own immune response to control the infection, coupled with how it is given - as a single (prime), or double (prime and boost) injection into the arm muscle, has the potential to be an innovative therapy to address this high global unmet medical need for patients with chronic HBV."
"The dosing of these first patients, in our lead VRON-0200 chronic HBV Phase 1b study, represents a major milestone in Virion's mission of bringing innovative immunotherapies to patients with cancer and chronic infectious diseases," said Virion's CEO, Dr. Andrew Luber. "Targeting T cell activation, via checkpoint modification, is unique to Virion. This first study, using our first checkpoint modifier, gD, not only benefits patients with chronic hepatitis B, but also, provides useful information for our proprietary platform technologies and pipeline, including VRON-0300, which is in development for patients with advanced solid tumours," Luber added.
Ocean Biomedical co-founder and executive chairman Dr. Chirinjeev Kathuria, commented: "This is another major clinical and business value inflection point for our company. Treatments for chronic HBV are in high demand and could capture an estimated global market of $6.5+ billion by 2032. Companies at a similar stage as our JV's VRON-0200 study, have seen large steps up in value. For example, VIR Biotechnology's value increased by over $3.6 billion dollars after they reported their initial 8 patient phase 1 data. Ocean is pleased to partner with Virion in bringing this high-need, high-value treatment – aiming for a functional cure - to patients with chronic HBV around the world."
VRON-0200 is a therapeutic immunotherapy, administered by intramuscular injection, designed with the goal of providing a functional cure for chronic HBV infection. While the virus itself stimulates HBV-specific CD8+?T cells, for those patients that can't clear the initial infection, their T cells soon become exhausted, placing limits on their ability to proliferate and control the virus. Preclinical data support the hypothesis that VRON-0200, through checkpoint modification, can amplify, broaden, and enhance T cell responses to include T cells that are not normally activated during a chronic HBV infection, which results in improved viral control.
Virion Therapeutics, LLC is a clinical-stage company developing novel T cell-based immunotherapies to cure cancer and chronic infectious diseases that utilize proprietary genetically encoded checkpoint modifiers (CPMs) to enhance and broaden CD8+ T cell responses to a tumour or chronic infection.
Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centres.
http://www.pharmabiz.com/NewsDetails.aspx?aid=163253&sid=2
$OCEA
Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day
Ocean Biomedical’s Oncology Platform currently consists of 27 Patents Issued or Pending.
Ocean Biomedical’s first-in-class anti-CHi3L1 therapeutic immunotherapy program has shown compounding efficacy in multiple lung cancer models while simultaneously inhibiting multiple oncogenic pathways, including hard-to-treat Non-Small Cell Lung Cancer (NSCLC).
Providence, RI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- On World Lung Cancer Day, Ocean Biomedical, Inc. (NASDAQ: OCEA) is sharing details of its multi-pronged Lung Cancer Program built on novel immunotherapy discoveries by Scientific Co-founder Dr. Jack A. Elias. He and his team have revealed that Chitinase 3-like-1 (CHi3L1) is a master regulator that inhibits antitumor immune responses. Ocean Biomedical’s lung cancer program is advancing several approaches to reversing immune system suppression caused by CHi3L1 alone and in combination with other immunotherapy pathways. These programs suppress primary and metastatic tumor growth in multiple animal models and have potential use in multiple forms of visceral cancers. In recent studies, Ocean Biomedical’s programs have demonstrated up to 95% reduction in primary and metastatic tumor burden in mouse models of lung cancer.
Anti-CHi3L1 monoclonal immunotherapy. The first step in this tumor reduction approach has stemmed from effectively reversing immune system suppression through binding CHi3L1 polypeptides with Ocean Biomedical’s proprietary immunoglobulin antibody. This monoclonal approach has yielded dramatic reduction in mouse lung tumor burden similar to current, cutting-edge monoclonal therapeutics (imaging below), creating the possibility of a new cancer immunotherapy option for patients who have poor response to existing treatments. Ocean’s monoclonal antibody targeting CHi3L1 was awarded a U.S. patent in June 2023 not only for application in lung cancer, but potential application in prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, and melanoma as well.
https://ml.globenewswire.com/Resource/Download/41e72328-0ab4-42c3-b8dd-2fcfb84068f5
Multiple Bispecific Immunotherapy Pathways. Building on the monoclonal antibody approach, Ocean Biomedical is developing groundbreaking bispecific antibodies that target CHi3L1 in combination with other known suppressors of tumor growth and development. This approach results in the simultaneous targeting of several major cancer pathways. Each bispecific candidate has been shown to substantially multiply effectiveness compared to current, established mono-focused immuno-therapeutics. This novel approach builds on one of the most exciting developments in cancer research in recent years - the realization that evasion of the body’s immune system is essential for tumor growth, progression, and resistance to treatments, especially through the suppression of T-cell responses and the stimulation of natural immune checkpoints. These advances have led to some successful lung cancer therapeutics that target PD1, PDL1, and CTLA-4, which individually all have roles in suppressing the immune system.
Ocean Biomedical is working to create a new generation of cancer therapeutics. In separate new approaches targeting PD1 and CTLA4, each in combination with anti-CHi3L1, the company’s bispecific therapeutic candidates have created lung cancer tumor suppression of 85%–95% (images below). Both bispecific approaches have pending patents in the U.S. and internationally, with claims extending beyond lung cancer to potential use in multiple additional cancers, including glioblastoma multiforme.
Anti-CHi3L1+Anti-PD1 bispecific immunotherapy. One of the currently effective cancer immunotherapies targets Programmed Cell Death Receptors, often designated “PD1” and its ligand “PDL1.” In results of one study testing the efficacy of the monospecific and bispecific antibodies by culturing tumor cells and human T lymphocyte cells together in the presence of varying combinations of our antibodies (results illustrated below), anti-PD1 caused the T cells to kill approximately 20% of the tumor cells and Ocean’s monospecific anti-CHi3L1 was comparably effective. When the two monospecific antibodies (anti-CHi3L1 and anti-PD1) were administered individually and at the same time an additive effect was seen with 40% of the tumor cells being killed. Pushing a step further, when Dr. Elias’ team tested the bispecific antibody that targeted CHi3L1 and PD1 greater than 90% of the tumor cells were killed. Thus, in multiple in vitro and mouse model lung cancer tests, the bispecific antibody that simultaneously targets CHi3L1 and PD1 has a remarkable, synergistic impact leading to tumor reduction that more than quadruples the impact of anti-PD1 alone.
https://ml.globenewswire.com/Resource/Download/29aff50e-37b7-4208-9841-fdd944fe5baa
Anti-CHi3L1+Anti-CTLA4 bispecific immunotherapy. In addition to the PD1 pathway, Ocean Biomedical is also targeting the immune checkpoint inhibitor CTLA4, another established immunotherapy pathway. The efficacy of these monospecific and bispecific antibodies has been tested in mouse model experiments (results shown below), where malignant melanoma tumor cells are released into the mouse circulation and their ability to spread (metastasize) to the lung is evaluated by quantitating the black pleural tumor colonies that develop in the presence of varying combinations of Ocean’s antibodies. Shown below, anti-CTLA4 decreased tumor metastasis by approximately 40% cells and Ocean’s monospecific anti-CHi3L1 was comparably effective. When the two monospecific antibodies (anti-CHi3L1 and anti-CTLA4) were administered individually and at the same time an additive effect was seen with a 60% decrease in pleural colonies (column 4). When the bispecific antibody that simultaneously targeted CHi3L1 and CTLA4 was employed there was a more than 80% decrease in metastasis (column 5).
https://ml.globenewswire.com/Resource/Download/9ef371f5-587a-4f48-bc2e-1acf82d22994
Multiple Pathways, Multiple Cancers. On several fronts, Ocean Biomedical is advancing lung cancer treatment candidates that have the ability to target multiple tumor suppressing pathways at the same time, and early indications show potential for multiplying the effectiveness of current immuno-oncology products, generating surprising, synergistic outcomes. Because these candidates are building on evolving understanding of how cancer cells subvert and attenuate natural immune responses, each candidate has potential application against a broad range of cancers. In a recently published independent study, the anti-CHi3L1 monoclonal has shown effectiveness in controlling some of the most harmful pathways in the universally lethal brain cancer, glioblastoma. In total, Ocean Biomedical’s oncology platform has garnered 27 issued or pending patents, already covering ‘method of use’ in nine unique cancers, including prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma, and lung cancer.
https://ml.globenewswire.com/Resource/Download/c1b42f7f-a2de-4ad3-913a-3830fba81cab
“We are making discoveries that we believe will drive cancer research, and eventually treatment and patient outcomes, forward,” said Dr. Elias. “This pathway discovery is an unprecedented leap, because if you control CHi3L1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways.”
“On World Lung Cancer Day, we are proud to be part of the global effort to cure this terrible disease,” commented Ocean Biomedical’s CEO, Elizabeth Ng. We are working on the systematic steps needed to progress the anti-CHi3L1 antibodies into the clinic to potentially become impactful new cancer therapeutics.”
“Non-Small Cell Lung Cancer alone affects nearly 500,000 people in the U.S.,“ commented Dr. Chirinjeev Kathuria, Ocean Biomedical’s co-founder and Executive Chairman. “These discoveries have the potential to save thousands of lives of people affected not just by lung metastasis, and glioblastoma, but also other forms of cancer such as breast, prostate and melanoma.”
About Jack A. Elias
Dr. Jack A. Elias is the former Chair of Yale’s Department of Internal Medicine, Dean Emeritus of Medicine and Biological Sciences at Brown University, and current Professor of Translational Science, Medicine and Molecular Microbiology and Immunology at The Warren Alpert Medical School of Brown University. He is a leading pulmonary care specialist and research pioneer. In 2019, Dr. Elias co-founded Ocean Biomedical with several Brown University colleagues, alums, and experienced pharma business leaders to help address major unmet medical needs by accelerating more discovery science into needed therapeutics.
About Cancer Immunotherapy
Immunotherapy is an evolving approach to cancer therapeutics that enhances traditional treatments by activating a person’s own immune system to fight cancer. Immunotherapy can boost the immune system to find and attack cancer cells. Monoclonal antibodies are immune system proteins created to bind to specific targets on cancer cells or cells in the tumor growth environment. Ocean Biomedical’s monoclonal antibody targets a polypeptide (CHi3L1) that is associated with accelerated tumor growth in a wide range of cancers. By suppressing CHi3L1, Ocean Biomedical has been able to suppress primary and metastatic tumor growth in multiple animal models. As reflected in the newly issued patent, this unique immunotherapy approach has potential use in multiple forms of visceral cancers.
About Ocean Biomedical
Ocean Biomedical, Inc. (“Ocean Biomedical” or the “Company”) is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most.
To learn more, visit www.oceanbiomedical.com.
Forward-Looking Statements
The information included herein and in any oral statements made in connection herewith include “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. These forward-looking statements include but are not limited to: the expected timing and success of investigational new drug (“IND”) filings for our initial product candidates; statements regarding the expected timing of our IND-enabling studies; the frequency and timing of filing additional INDs; expectations regarding the availability and addition of future assets to our pipeline; the advantages of any of our pipeline assets and platforms; the potential benefits of our product candidates; potential commercial opportunities; the timing of key milestones for our programs; the future financial condition, results of operations, business strategy and plans, and objectives of management for future strategy and operations; and statements about industry trends and other companies in the industry. These forward-looking statements are based on various assumptions, whether or not identified herein, and on the current expectations of the Company’s management, and they are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions.
Any discoveries announced by the Company are based solely on laboratory and animal studies. The Company has not conducted any studies that show similar efficacy or safety in humans. There can be no assurances that any treatment tested by the Company will prove safe or effective in humans, and any clinical benefit of any such treatment is subject to clinical trials and ultimate approval of its use in patients by the FDA. Such approval, if granted, could be years away.
Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are not guarantees of future performance, conditions, or results, and involve a number of known and unknown risks, uncertainties, assumptions, and other important factors, many of which are outside the control of the Company that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties that are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and in other documents to be filed by the Company from time to time with the SEC and which are and will be available at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. We do not undertake any obligation to update any forward-looking statements made by us. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this filing. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Ocean Biomedical Investor Relations
OCEANIR@westwicke.com
Ocean Biomedical Media Relations
OCEANPR@westwicke.com
Kevin Kertscher
Communications Director
Source: Ocean Biomedical, Inc.
© 2023 GlobeNewswire, Inc.
https://www.otcmarkets.com/stock/OCEA/news/story?e&id=2592694
$OCEA
$OCEA - 👆Up 17% Pre-Market/ Current Price $5.53
Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day
Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer Day
Great start!!
GLTA $OCEA
$OCEA: She goneeeeeeeeeeeee.......... got a $17 PT today
Saw it at $7 earlier.... now $7.90
GO $OCEA
Fools being manipulated into selling by the machines of corruption,and being robbed blind.
being added to russel. y anyone selling should be buying. there r like million shares or alot less in the float. when they start buying there will be very little shares left
up up and away and they have to buy no matter the price
thx, called them co hasnt put the price out.
It can hit $10.00+ in the short term.
That info doesn't seem available on line, probably can get it from your broker.
whats the buy price on the warrants? thx
Total numb nuts selling the warrants at $0.3375, future chasers much higher.
OCEA Extreme FUD here last 2 Hours Oversold
Can see this doing $20-30 today. Micro float, shorts are about to get stopped out in the mid 10s
Big move today!!
Yeah!!
$OCEA
Why Ocean Biomedical Shares Are Surging
Ocean Biomedical Inc
Shares are trading higher Tuesday after the company announced a patent award for novel cancer immunotherapy treatment.
What Happened: Ocean Biomedical co-founder Jack Elias was issued a broad patent for a cancer immunotherapy discovery that involves the company's proprietary immunoglobulin antibody.
The discovery is related to reversing immune system suppression by binding chitinase 3-like-1 polypeptides with the antibody, which has been shown to suppress primary and metastatic tumor growth in multiple animal models and could also potentially be used in various forms of visceral cancers.
The patent was granted for prostate cancer, colon cancer, rectal cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma and lung cancer.
"This pathway discovery is an unprecedented leap forward, because if you control CHi3L1, you don't just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways," Elias said.
https://www.benzinga.com/news/23/05/32528303/why-ocean-biomedical-shares-are-surging
$OCEA
Forecasting malaria outbreaks
Forecasting malaria outbreaks https://t.co/7UZSOk3tU5
— Ocean Biomedical (@OceanBiomedical) March 10, 2023
Ocean Biomedical's Scientific Co-founder, Dr. Jack Elias, shares detailed research data on Anti-Tumor Pathway Discoveries & their potential for treatment of Non-Small Cell #LungCancer, #Melanoma, and #Glioblastoma at meeting hosted by @BrownUCancer #OCEA https://t.co/Tobn256BP4 pic.twitter.com/uTEBSrnfpV
— Ocean Biomedical (@OceanBiomedical) March 9, 2023
CONGRAT$
big miss for me
Cool!! Nice gains!
$EPAZ also up today!! Weeeee!!
GLTA $OCEA
$OCEA: Only one thing better than $OCEA today..................
$SIVB puts..........
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171403946
YOU'RE WELCOME !!!!!!!!!
GO $OCEA
$OCEA: Now 10.50 babyyyyyyyyyyyyyyyyyyyyyyyyyyyyy THANK YOU
Money going into $TMNA.
Love it love it LOVE IT !!!!!!!!!!!
GO $OCEA
Break past 9.80 and 11.00 is in sight
It still is!
$OCEA
Followers
|
10
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
112
|
Created
|
03/09/23
|
Type
|
Free
|
Moderators |
This section maintained by INV4 |
Ocean Biomedical (NASDAQ: OCEA) Shares Detailed Research Data on Anti-Tumor Pathway Discoveries and Their Potential for Treatment of Non-Small Cell Lung Cancer, Metastatic Melanoma, and Glioblastoma by Scientific Co-founder Providence, RI, March 09, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA). Ocean Biomedical’s Scientific Co-founder, Dr. Jack A. Elias, MD, presented details of his previously published discoveries that have potential application for tumor suppression across multiple cancer pathways at the Legorreta Cancer Center’s recent meeting in Providence. In his talk, Dr. Elias focused on his lab’s groundbreaking work on understanding the development and progression of lung cancer, especially the role of Chitinase 3-like-1 (CHI3L1). He also shared details of his novel therapeutic discoveries that show the efficacy of monospecific and bispecific antibodies against CHI3L1 and PD-1 as therapies for non-small cell lung cancer, and glioblastoma multiforme. Ocean Biomedical is currently working to move these antibody therapeutic discoveries towards Phase 1 clinical trials. In his recent talk, Dr. Elias shared details of his team’s discoveries of the role CHI3L1 in regulating primary and metastatic lung cancer, glioblastoma multiforme, and broader oncogenic pathways. He discussed the inverse correlation of circulating CHI3L1 with prognosis for disease progression and survival, and the step-by-step experimentation done to create effective monospecific antibodies, and then a powerful bispecific antibody that has a multiplicative effect on reducing tumor by triggering tumor apoptosis in metastatic melanoma, glioblastoma, and non-small cell lung cancer. In his talk, Dr. Elias additionally shared the potential for extending the regulation of this “master anti-tumor pathway” to other cancers, and promising research that reveals an additional anti-tumor pathway targeting T-cell co-stimulation using the inducible co-stimulator (ICOS) and its ligand ICOSL, and Cluster of Differentiation 28 (CD28) and its ligands B7-1 and B7-2. The Methods and Compositions patents that have been granted to Dr. Elias for these mono-specific and bi-specific antibody approaches have been granted for use in multiple cancer types, including Prostate Cancer, Colon Cancer, Rectal Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, Malignant Melanoma, and Lung Cancer. Dr. Elias, who is the former Chair of Yale’s Department of Medicine, and the Dean Emeritus of Medicine and Biological Sciences at Brown University summed up his team’s work saying, “It was great to share the details of our work with colleagues at the Legorreta Cancer Center. In narrowing in on major pathways that are applicable across cancer types, we believe we are making discoveries that will drive treatment and patient outcomes forward. Realizing that if you control CHI3L1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways is an unprecedented leap forward and we are very pleased to be accelerating this research with Ocean Biomedical.” “We are excited to see the reactions to Dr. Elias's discoveries that CHI3L1 is a critical regulator of T-cell activity. These therapies have the potential to save lives of people affected not just by lung metastasis, and melanoma, but also non-small cell lung cancer, glioblastoma and other forms of cancer,” said Dr. Chirinjeev Kathuria, co-founder and Executive Chairman. Malignant melanoma, a very serious skin cancer with a 22.5% five-year survival for patients with Stage IV disease, can metastasize to other organs. Once it has spread to other organs, it is difficult to treat – in some cases, it can spread to the lungs and result in non-small cell lung cancer (NSCLC), a major unmet medical need that accounts for 85% of pulmonary malignancies and affects approximately 450,000 individuals. In over 50% of affected NSCLC patients, tumors are not diagnosed until the advanced stages, with metastatic spread that precludes curative surgical resection. Recent studies of NSCLC have highlighted the effectiveness of immune checkpoint inhibitor (ICPI), therapies that block cancer-proliferating proteins like CHI3L1 and help the patient’s body recognize and attack cancer cells. Unfortunately, only a minority of patients respond to these therapies and the responses are often not durable. Recent studies from Ocean Biomedical have demonstrated that CHI3L1 is a critical regulator of a number of key cancer-causing pathways, highlighting its ability to inhibit tumor cell death (apoptosis), its inhibition of the expression of the tumor suppressors P53 and PTEN and its stimulation of the B-RAF protooncogene. Most recently Dr. Elias’s research team has discovered that CHI3L1 is a “master regulator” of ICPI, including key elements of the PD-1 and CTLA4 pathways. In accord with the importance of these pathways, Ocean has also generated antibodies: 1.) a monoclonal antibody against CHI3L1, 2.) bispecific antibodies that simultaneously target CHI3L1 and PD-1, and 3.) a new bispecific antibody that simultaneously targets CHI3L1 and CTLA4. The impressive ability of these bispecific antibodies to control primary and metastatic lung cancer in murine experimental modeling systems have been discussed in detail in an earlier article in the Journal of Clinical Investigation, and this expanded approach in Frontiers in Immunology. Suren Ajjarapu, a Director of Ocean Biomedical commented, “Immunotherapy is the future of cancer care, and we are proud to be partnering with Dr. Elias in advancing the development of his cancer treatments, along with his fibrosis treatments, and our global malaria program. We look forward to bringing all of these therapies to patients as Ocean Biomedical moves forward, for the long-term shareholder value and the continued advancement of medical science.” About Ocean Biomedical Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most. To learn more, visit www.oceanbiomedical.com. Ocean Biomedical Investor Relations OCEANIR@westwicke.com Ocean Biomedical Media Relations OCEANPR@westwicke.com Kevin Kertscher Communications Director |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |